SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '6UY'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	6 / 12	ALA A 228 GLU A 250 LEU A 263 CYH A 286 LEU A 320 HIS A 329	6UY A 501 (-3.4A) 6UY A 501 (-4.3A) None 6UY A 501 (-4.3A) None None	0.93A	1uwhA-5ko1A: 26.9	1uwhA-5ko1A: 26.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	ALA A 228 LYS A 230 GLU A 250 LEU A 263 CYH A 286 LEU A 320 HIS A 329	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None 6UY A 501 (-4.3A) None None	0.88A	1uwhB-5ko1A: 26.8	1uwhB-5ko1A: 26.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	6 / 12	ALA A 228 GLU A 250 LEU A 263 CYH A 286 LEU A 320 HIS A 329	6UY A 501 (-3.4A) 6UY A 501 (-4.3A) None 6UY A 501 (-4.3A) None None	0.93A	1uwjA-5ko1A: 8.6	1uwjA-5ko1A: 26.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	6 / 12	ALA A 228 GLU A 250 LEU A 263 CYH A 286 LEU A 320 HIS A 329	6UY A 501 (-3.4A) 6UY A 501 (-4.3A) None 6UY A 501 (-4.3A) None None	0.92A	1uwjB-5ko1A: 8.6	1uwjB-5ko1A: 26.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 GLY A 289 LEU A 338 ALA A 348	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A) 6UY A 501 (-3.4A)	0.76A	2gqgA-5ko1A: 26.8	2gqgA-5ko1A: 30.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 MET A 254 ILE A 281 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None None 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.74A	2gqgA-5ko1A: 26.8	2gqgA-5ko1A: 30.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y6O_A_1N1A1892_1 (EPHRIN TYPE-A RECEPTOR 4)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	ALA A 228 LYS A 230 GLU A 250 MET A 254 ILE A 281 TYR A 285 GLY A 289 LEU A 338	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.64A	2y6oA-5ko1A: 28.2	2y6oA-5ko1A: 28.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 MET A 254 ILE A 281 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None None 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.81A	2zvaA-5ko1A: 28.1	2zvaA-5ko1A: 28.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AOC_C_ERYC3402_0 (ACRIFLAVINE RESISTANCE PROTEIN B)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	5 / 12	MET A 283 PHE A 232 ILE A 281 LEU A 317 GLU A 327	6UY A 501 (-3.8A) None None None None	1.26A	3aocC-5ko1A: undetectable	3aocC-5ko1A: 15.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K54_A_1N1A1_1 (TYROSINE-PROTEIN KINASE BTK)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	9 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 MET A 254 ILE A 281 TYR A 285 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.83A	3k54A-5ko1A: 27.4	3k54A-5ko1A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	5 / 12	ALA A 228 LYS A 230 LEU A 263 CYH A 286 PHE A 350	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None 6UY A 501 (-4.3A) None	0.79A	3og7A-5ko1A: 26.1	3og7A-5ko1A: 26.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ZBF_A_VGHA3000_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	5 / 12	LEU A 209 ALA A 228 LEU A 263 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) None 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.38A	3zbfA-5ko1A: 28.2	3zbfA-5ko1A: 28.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_A_0LIA1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	ALA A 228 LYS A 230 LEU A 263 ILE A 281 HIS A 329 LEU A 338 ALA A 348	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None None None 6UY A 501 (-4.5A) 6UY A 501 (-3.4A)	0.73A	4c8bA-5ko1A: 27.3	4c8bA-5ko1A: 28.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_B_0LIB1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	ALA A 228 LYS A 230 ILE A 262 LEU A 263 HIS A 329 LEU A 338 ALA A 348	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None None None 6UY A 501 (-4.5A) 6UY A 501 (-3.4A)	0.67A	4c8bB-5ko1A: 27.1	4c8bB-5ko1A: 28.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 MET A 254 ILE A 281 TYR A 285 GLY A 289	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A)	0.58A	4mxoA-5ko1A: 27.1	4mxoA-5ko1A: 26.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 ILE A 281 TYR A 285 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.67A	4mxoB-5ko1A: 27.5	4mxoB-5ko1A: 26.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 ILE A 281 TYR A 285 GLY A 289	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A)	0.76A	4mxxA-5ko1A: 27.3	4mxxA-5ko1A: 26.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 MET A 254 TYR A 285 GLY A 289	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A)	0.75A	4mxxA-5ko1A: 27.3	4mxxA-5ko1A: 26.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	LEU A 209 ALA A 228 LYS A 230 MET A 254 TYR A 285 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.74A	4mxxA-5ko1A: 27.3	4mxxA-5ko1A: 26.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXY_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	LEU A 209 ALA A 228 GLU A 250 ILE A 281 MET A 283 TYR A 285 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.3A) None 6UY A 501 (-3.8A) 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.85A	4mxyA-5ko1A: 27.5	4mxyA-5ko1A: 26.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXY_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	LEU A 209 ALA A 228 LYS A 230 ILE A 281 MET A 283 TYR A 285 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None 6UY A 501 (-3.8A) 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.75A	4mxyA-5ko1A: 27.5	4mxyA-5ko1A: 26.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXZ_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	LEU A 209 ALA A 228 GLU A 250 ILE A 281 MET A 283 TYR A 285 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.3A) None 6UY A 501 (-3.8A) 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.85A	4mxzA-5ko1A: 27.5	4mxzA-5ko1A: 26.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXZ_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	LEU A 209 ALA A 228 LYS A 230 ILE A 281 MET A 283 TYR A 285 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None 6UY A 501 (-3.8A) 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.75A	4mxzA-5ko1A: 27.5	4mxzA-5ko1A: 26.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	6 / 12	ALA A 228 LYS A 230 CYH A 286 GLY A 289 HIS A 329 LEU A 338	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) 6UY A 501 ( 4.3A) None 6UY A 501 (-4.5A)	0.51A	4u0iA-5ko1A: 26.7	4u0iA-5ko1A: 26.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	6 / 11	LEU A 209 ALA A 228 GLY A 289 ASN A 336 LEU A 338 ALA A 348	None 6UY A 501 (-3.4A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.4A) 6UY A 501 (-4.5A) 6UY A 501 (-3.4A)	0.62A	4wa9A-5ko1A: 23.2	4wa9A-5ko1A: 29.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_C_ANWC601_0 (RHODOPSIN KINASE)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	4 / 6	LEU A 209 ALA A 228 MET A 283 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-3.8A) 6UY A 501 (-4.5A)	0.93A	4wboC-5ko1A: 20.7	4wboC-5ko1A: 21.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WKQ_A_IREA1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 MET A 254 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.83A	4wkqA-5ko1A: 26.2	4wkqA-5ko1A: 26.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_B_1N1B600_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	ALA A 228 LYS A 230 GLU A 250 MET A 254 ILE A 281 TYR A 285 GLY A 289 LEU A 338	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.70A	4xliB-5ko1A: 27.3	4xliB-5ko1A: 30.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_B_1N1B600_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	8 / 12	LEU A 209 ALA A 228 LYS A 230 GLU A 250 MET A 254 ILE A 281 TYR A 285 GLY A 289	None 6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A)	0.66A	4xliB-5ko1A: 27.3	4xliB-5ko1A: 30.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	5 / 12	ALA A 228 LYS A 230 LEU A 263 CYH A 286 PHE A 350	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None 6UY A 501 (-4.3A) None	0.78A	4xv2B-5ko1A: 26.1	4xv2B-5ko1A: 26.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	5 / 12	ALA A 228 LYS A 230 LEU A 263 CYH A 286 PHE A 350	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None 6UY A 501 (-4.3A) None	0.85A	5cswA-5ko1A: 25.3	5cswA-5ko1A: 26.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	5 / 12	ALA A 228 LYS A 230 LEU A 263 CYH A 286 PHE A 350	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None 6UY A 501 (-4.3A) None	0.84A	5cswB-5ko1A: 25.2	5cswB-5ko1A: 26.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	5 / 12	LEU A 209 ALA A 228 LEU A 263 GLY A 289 LEU A 338	None 6UY A 501 (-3.4A) None 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.68A	5h2uC-5ko1A: 24.9	5h2uC-5ko1A: 28.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	ALA A 228 LYS A 230 GLU A 250 LEU A 263 CYH A 286 LEU A 320 HIS A 329	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None 6UY A 501 (-4.3A) None None	0.86A	5hi2A-5ko1A: 26.5	5hi2A-5ko1A: 26.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9X_A_DB8A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	ALA A 228 LYS A 230 GLU A 250 ILE A 281 TYR A 285 GLY A 289 LEU A 338	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.62A	5i9xA-5ko1A: 28.6	5i9xA-5ko1A: 29.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9Y_A_1N1A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	7 / 12	ALA A 228 LYS A 230 GLU A 250 MET A 254 TYR A 285 GLY A 289 LEU A 338	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) 6UY A 501 (-4.3A) None 6UY A 501 ( 4.8A) 6UY A 501 ( 4.3A) 6UY A 501 (-4.5A)	0.61A	5i9yA-5ko1A: 28.6	5i9yA-5ko1A: 29.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W5V_A_ANWA701_0 (SERINE/THREONINE-PRO TEIN KINASE TBK1)	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	5 / 9	LEU A 209 ALA A 228 MET A 283 CYH A 286 GLY A 289	None 6UY A 501 (-3.4A) 6UY A 501 (-3.8A) 6UY A 501 (-4.3A) 6UY A 501 ( 4.3A)	0.86A	5w5vA-5ko1A: 13.9	5w5vA-5ko1A: 17.71

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",6,"ALA A 228;GLU A 250;LEU A 263;CYH A 286;LEU A 320;HIS A 329","6UY A 501 (-3.4A);6UY A 501 (-4.3A);None;6UY A 501 (-4.3A);None;None","0.93A","1uwhA-5ko1A:26.9",null],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"ALA A 228;LYS A 230;GLU A 250;LEU A 263;CYH A 286;LEU A 320;HIS A 329","6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;6UY A 501 (-4.3A);None;None","0.88A","1uwhB-5ko1A:26.8","1uwhA-5ko1A:26.16"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",6,"ALA A 228;GLU A 250;LEU A 263;CYH A 286;LEU A 320;HIS A 329","6UY A 501 (-3.4A);6UY A 501 (-4.3A);None;6UY A 501 (-4.3A);None;None","0.93A","1uwjA-5ko1A:8.6","1uwhB-5ko1A:26.16"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",6,"ALA A 228;GLU A 250;LEU A 263;CYH A 286;LEU A 320;HIS A 329","6UY A 501 (-3.4A);6UY A 501 (-4.3A);None;6UY A 501 (-4.3A);None;None","0.92A","1uwjB-5ko1A:8.6","1uwjA-5ko1A:26.16"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;GLY A 289;LEU A 338;ALA A 348","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A);6UY A 501 (-3.4A)","0.76A","2gqgA-5ko1A:26.8","1uwjB-5ko1A:26.16"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;MET A 254;ILE A 281;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;None;6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.74A","2gqgA-5ko1A:26.8","2gqgA-5ko1A:30.39"],["2Y6O_A_1N1A1892_1","EPHRIN TYPE-A RECEPTOR 4","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"ALA A 228;LYS A 230;GLU A 250;MET A 254;ILE A 281;TYR A 285;GLY A 289;LEU A 338","6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.64A","2y6oA-5ko1A:28.2","2gqgA-5ko1A:30.39"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;MET A 254;ILE A 281;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;None;6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.81A","2zvaA-5ko1A:28.1","2y6oA-5ko1A:28.43"],["3AOC_C_ERYC3402_0","ACRIFLAVINE RESISTANCE PROTEIN B","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",5,"MET A 283;PHE A 232;ILE A 281;LEU A 317;GLU A 327","6UY A 501 (-3.8A);None;None;None;None","1.26A","3aocC-5ko1A:undetectable","2zvaA-5ko1A:28.43"],["3K54_A_1N1A1_1","TYROSINE-PROTEIN KINASE BTK","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",9,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;MET A 254;ILE A 281;TYR A 285;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.83A","3k54A-5ko1A:27.4","3aocC-5ko1A:15.46"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",5,"ALA A 228;LYS A 230;LEU A 263;CYH A 286;PHE A 350","6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;6UY A 501 (-4.3A);None","0.79A","3og7A-5ko1A:26.1","3k54A-5ko1A:27.10"],["3ZBF_A_VGHA3000_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",5,"LEU A 209;ALA A 228;LEU A 263;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);None;6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.38A","3zbfA-5ko1A:28.2","3og7A-5ko1A:26.51"],["4C8B_A_0LIA1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"ALA A 228;LYS A 230;LEU A 263;ILE A 281;HIS A 329;LEU A 338;ALA A 348","6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;None;None;6UY A 501 (-4.5A);6UY A 501 (-3.4A)","0.73A","4c8bA-5ko1A:27.3","3zbfA-5ko1A:28.14"],["4C8B_B_0LIB1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"ALA A 228;LYS A 230;ILE A 262;LEU A 263;HIS A 329;LEU A 338;ALA A 348","6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;None;None;6UY A 501 (-4.5A);6UY A 501 (-3.4A)","0.67A","4c8bB-5ko1A:27.1","4c8bA-5ko1A:28.19"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;MET A 254;ILE A 281;TYR A 285;GLY A 289","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A)","0.58A","4mxoA-5ko1A:27.1","4c8bB-5ko1A:28.19"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;ILE A 281;TYR A 285;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.67A","4mxoB-5ko1A:27.5","4mxoA-5ko1A:26.58"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;ILE A 281;TYR A 285;GLY A 289","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A)","0.76A","4mxxA-5ko1A:27.3","4mxoB-5ko1A:26.58"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;MET A 254;TYR A 285;GLY A 289","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A)","0.75A","4mxxA-5ko1A:27.3","4mxxA-5ko1A:26.25"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"LEU A 209;ALA A 228;LYS A 230;MET A 254;TYR A 285;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.74A","4mxxA-5ko1A:27.3","4mxxA-5ko1A:26.25"],["4MXY_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"LEU A 209;ALA A 228;GLU A 250;ILE A 281;MET A 283;TYR A 285;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.3A);None;6UY A 501 (-3.8A);6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.85A","4mxyA-5ko1A:27.5","4mxxA-5ko1A:26.25"],["4MXY_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"LEU A 209;ALA A 228;LYS A 230;ILE A 281;MET A 283;TYR A 285;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;6UY A 501 (-3.8A);6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.75A","4mxyA-5ko1A:27.5","4mxyA-5ko1A:26.58"],["4MXZ_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"LEU A 209;ALA A 228;GLU A 250;ILE A 281;MET A 283;TYR A 285;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.3A);None;6UY A 501 (-3.8A);6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.85A","4mxzA-5ko1A:27.5","4mxyA-5ko1A:26.58"],["4MXZ_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"LEU A 209;ALA A 228;LYS A 230;ILE A 281;MET A 283;TYR A 285;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;6UY A 501 (-3.8A);6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.75A","4mxzA-5ko1A:27.5","4mxzA-5ko1A:26.58"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",6,"ALA A 228;LYS A 230;CYH A 286;GLY A 289;HIS A 329;LEU A 338","6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);6UY A 501 ( 4.3A);None;6UY A 501 (-4.5A)","0.51A","4u0iA-5ko1A:26.7","4mxzA-5ko1A:26.58"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",6,"LEU A 209;ALA A 228;GLY A 289;ASN A 336;LEU A 338;ALA A 348","None;6UY A 501 (-3.4A);6UY A 501 ( 4.3A);6UY A 501 (-4.4A);6UY A 501 (-4.5A);6UY A 501 (-3.4A)","0.62A","4wa9A-5ko1A:23.2","4u0iA-5ko1A:26.38"],["4WBO_C_ANWC601_0","RHODOPSIN KINASE","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",4,"LEU A 209;ALA A 228;MET A 283;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-3.8A);6UY A 501 (-4.5A)","0.93A","4wboC-5ko1A:20.7","4wa9A-5ko1A:29.78"],["4WKQ_A_IREA1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;MET A 254;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.83A","4wkqA-5ko1A:26.2","4wboC-5ko1A:21.13"],["4XLI_B_1N1B600_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"ALA A 228;LYS A 230;GLU A 250;MET A 254;ILE A 281;TYR A 285;GLY A 289;LEU A 338","6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.70A","4xliB-5ko1A:27.3","4wkqA-5ko1A:26.04"],["4XLI_B_1N1B600_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",8,"LEU A 209;ALA A 228;LYS A 230;GLU A 250;MET A 254;ILE A 281;TYR A 285;GLY A 289","None;6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A)","0.66A","4xliB-5ko1A:27.3","4xliB-5ko1A:30.41"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",5,"ALA A 228;LYS A 230;LEU A 263;CYH A 286;PHE A 350","6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;6UY A 501 (-4.3A);None","0.78A","4xv2B-5ko1A:26.1","4xliB-5ko1A:30.41"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",5,"ALA A 228;LYS A 230;LEU A 263;CYH A 286;PHE A 350","6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;6UY A 501 (-4.3A);None","0.85A","5cswA-5ko1A:25.3","4xv2B-5ko1A:26.82"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",5,"ALA A 228;LYS A 230;LEU A 263;CYH A 286;PHE A 350","6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;6UY A 501 (-4.3A);None","0.84A","5cswB-5ko1A:25.2","5cswA-5ko1A:26.73"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",5,"LEU A 209;ALA A 228;LEU A 263;GLY A 289;LEU A 338","None;6UY A 501 (-3.4A);None;6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.68A","5h2uC-5ko1A:24.9","5cswB-5ko1A:26.73"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"ALA A 228;LYS A 230;GLU A 250;LEU A 263;CYH A 286;LEU A 320;HIS A 329","6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;6UY A 501 (-4.3A);None;None","0.86A","5hi2A-5ko1A:26.5","5h2uC-5ko1A:28.38"],["5I9X_A_DB8A1001_1","EPHRIN TYPE-A RECEPTOR 2","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"ALA A 228;LYS A 230;GLU A 250;ILE A 281;TYR A 285;GLY A 289;LEU A 338","6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.62A","5i9xA-5ko1A:28.6","5hi2A-5ko1A:26.82"],["5I9Y_A_1N1A1001_1","EPHRIN TYPE-A RECEPTOR 2","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",7,"ALA A 228;LYS A 230;GLU A 250;MET A 254;TYR A 285;GLY A 289;LEU A 338","6UY A 501 (-3.4A);6UY A 501 (-4.0A);6UY A 501 (-4.3A);None;6UY A 501 ( 4.8A);6UY A 501 ( 4.3A);6UY A 501 (-4.5A)","0.61A","5i9yA-5ko1A:28.6","5i9xA-5ko1A:29.25"],["5W5V_A_ANWA701_0","SERINE\/THREONINE-PROTEIN KINASE TBK1","5ko1","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","Homo sapiens",5,"LEU A 209;ALA A 228;MET A 283;CYH A 286;GLY A 289","None;6UY A 501 (-3.4A);6UY A 501 (-3.8A);6UY A 501 (-4.3A);6UY A 501 ( 4.3A)","0.86A","5w5vA-5ko1A:13.9","5i9yA-5ko1A:29.25"]]